Description: EGFR-Directed Therapy in Lung Cancer by So Yeon Kim, Daniel B. Costa, Daisuke Shibahara, Susumu Kobayashi, Balazs Halmos This Element describes the structural biology and pathophysiology of EGFR-mutant NSCLC and describes past, current, and future treatment options in different settings. It discusses the biology and recently approved treatment for EGFR-exon 20 insertion mutation and the treatment for the uncommon mutations. FORMAT Paperback CONDITION Brand New Publisher Description Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a clinically important driver alteration affecting approximately one-third of lung cancer patients. Treatments for EGFR-exon 19 deletion and exon 21 L858R NSCLC have evolved over the last decade from first-generation reversible tyrosine kinase inhibitors (TKI) to third-generation irreversible TKIs, of which osimertinib has been the widely accepted as first-line therapy. Despite survival improvement seen with osimertinib and its efficacy against acquired T790M mutation, resistance through on-target and off-target pathways eventually develop. This Element describes the structural biology and pathophysiology of EGFR-mutant NSCLC and discusses past, current, and future treatment options in the metastatic, neoadjuvant, and adjuvant settings. It describes the biology and recently approved treatment for EGFR-exon 20 insertion mutation and the treatment for the uncommon exon 18 (G719X), 20 (S768I), and 21 (L861Q) mutations. It also outlines the promising clinical applications of circulating tumor DNA (ctDNA). Table of Contents 1.Structural biology and mechanism of activation of EGFR; 2. EGFR-associated oncogenesis; 3. Tyrosine kinase inhibitors (TKIs) as targeted treatment for EGFR-mutant NSCLC; 4. EGFR-TKIs as adjuvant or neoadjuvant therapy; 5. EGFR-Exon 20 insertion mutations; 6. Resistance mechanisms and therapies in metastatic resistant EGFR-NSCLC; 7. Uncommon EGFR-activating mutations; 8. Immunotherapy in metastatic EGFR-mutant NSCLC; 9. Management of CNS disease and oligometastatic EGFR-mutant NSCLC; 10. ctDNA in EGFR-mutant NSCLC; 11. Guidelines and recommendations for EGFR-mutant NSCLC; References. Promotional This Element describes the pathophysiology and current and future management of EGFR-mutant non-small cell lung cancer. Promotional "Headline" This Element describes the pathophysiology and current and future management of EGFR-mutant non-small cell lung cancer. Details ISBN1009342304 Author Balazs Halmos Pages 75 Publisher Cambridge University Press Year 2023 ISBN-10 1009342304 ISBN-13 9781009342308 Publication Date 2023-01-26 UK Release Date 2023-01-26 Format Paperback Imprint Cambridge University Press Place of Publication Cambridge Country of Publication United Kingdom AU Release Date 2023-01-26 NZ Release Date 2023-01-26 Illustrations Worked examples or Exercises Series Elements in Molecular Oncology Alternative 9781009342285 DEWEY 616.994240695 Audience General We've got this At The Nile, if you're looking for it, we've got it. With fast shipping, low prices, friendly service and well over a million items - you're bound to find what you want, at a price you'll love! TheNile_Item_ID:168641872;
Price: 55.83 AUD
Location: Melbourne
End Time: 2024-12-24T03:15:53.000Z
Shipping Cost: 9.37 AUD
Product Images
Item Specifics
Restocking fee: No
Return shipping will be paid by: Buyer
Returns Accepted: Returns Accepted
Item must be returned within: 30 Days
Format: Paperback
ISBN-13: 9781009342308
Author: So Yeon Kim, Daniel B. Costa, Daisuke Shibahara
Type: Does not apply
Book Title: EGFR-Directed Therapy in Lung Cancer
Language: Does not apply
